Michael Barbella, Managing Editor02.14.23
Anika Therapeutics Inc. has begun the limited market release of its new RevoMotion Reverse Shoulder Arthroplasty (RSA) System, with the first surgeries performed in the United States.
The launch of the RevoMotion RSA System marks Anika’s entrance into the $800 million-plus U.S. reverse shoulder market—the fastest growing segment in shoulder arthroplasty—which projected to grow 11% annually through 2026.1 With RevoMotion's launch, surgeons can now address the full spectrum of shoulder arthroplasty procedures with Anika’s differentiated bone and motion preserving products. Current industry estimates are that there will be 200,000 shoulder arthroplasty procedures performed in the U.S this year.2
“The launch of RevoMotion is a significant step forward as Anika builds on the strong foundation for our multi-year growth strategy in joint preservation, one of the highest opportunity spaces in orthopedics, and enhances the value that we can provide to surgeons and their patients in both the ASC and hospital settings,” Anika Therapeutics President/CEO Cheryl R. Blanchard, Ph.D., said. “The surgeons who have used RevoMotion are excited about the bone preserving design and are seeing this play out clinically. This is truly a next-generation reverse shoulder system, which we designed based on a thorough evaluation of market needs, clinical results and surgeon and patient expectations. With the launch of RevoMotion, surgeons can now address the full spectrum of shoulder arthroplasty repairs, including the fastest growing segment of shoulder arthroplasty, reverse shoulders, with Anika products. RevoMotion marks the second of three key new product launches planned for 2023/2024 and complements the momentum we already have in other recent launches. In combination with the X-Twist Fixation System, Tactoset Injectable Bone Substitute, and a full portfolio of soft tissue repair products, Anika is well positioned to serve surgeon and patient needs focused on the shoulder and rotator cuff pathology. We look forward to continuing to enhance our comprehensive portfolio of solutions to restore active living, deliver accelerated growth and increase shareholder value.”
Key benefits of RevoMotion include:
The RevoMotion RSA System is engineered to uniquely preserve bone, while providing a personalized fit to the patient’s native anatomy. RevoMotion leverages design concepts first introduced by Anika with the Arthrosurface Joint Solutions OVOMotion with Inlay Glenoid. The OVOMotion product line provided new stemless total shoulder arthroplasty concepts to the industry, including a bone conserving, anatomic, non-spherical humeral head with an innovative inlay glenoid design. The RevoMotion system builds on OVO and OVOMotion principles of bone conservation and respecting natural patient anatomy.
“The RevoMotion Reverse Shoulder Arthroplasty System fills a vital place in Anika’s shoulder arthroplasty portfolio, which now offers the full line of solutions to meet my patients’ needs,” said Christopher Baker, M.D., of the Florida Orthopaedic Institute, Tampa, Fla. “RevoMotion offers significant advantages, including a 23mm diameter baseplate, the smallest threaded baseplate on the market. This allows the potential to save glenoid bone-stock and provides flexibility in positioning, allowing me to treat a variety of glenoid morphologies.”
Anika is initially offering the RevoMotion RSA System in the United States through a limited market release, with a full market release expected in late 2023.
Anika Therapeutics is a global joint preservation company focusing on high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, sports medicine soft tissue repair, and bone preserving joint technologies. Anika’s global operations are headquartered outside of Boston.
References
1, 2 2023E and 2022 SmartTRAK Data
3 Data on file
The launch of the RevoMotion RSA System marks Anika’s entrance into the $800 million-plus U.S. reverse shoulder market—the fastest growing segment in shoulder arthroplasty—which projected to grow 11% annually through 2026.1 With RevoMotion's launch, surgeons can now address the full spectrum of shoulder arthroplasty procedures with Anika’s differentiated bone and motion preserving products. Current industry estimates are that there will be 200,000 shoulder arthroplasty procedures performed in the U.S this year.2
“The launch of RevoMotion is a significant step forward as Anika builds on the strong foundation for our multi-year growth strategy in joint preservation, one of the highest opportunity spaces in orthopedics, and enhances the value that we can provide to surgeons and their patients in both the ASC and hospital settings,” Anika Therapeutics President/CEO Cheryl R. Blanchard, Ph.D., said. “The surgeons who have used RevoMotion are excited about the bone preserving design and are seeing this play out clinically. This is truly a next-generation reverse shoulder system, which we designed based on a thorough evaluation of market needs, clinical results and surgeon and patient expectations. With the launch of RevoMotion, surgeons can now address the full spectrum of shoulder arthroplasty repairs, including the fastest growing segment of shoulder arthroplasty, reverse shoulders, with Anika products. RevoMotion marks the second of three key new product launches planned for 2023/2024 and complements the momentum we already have in other recent launches. In combination with the X-Twist Fixation System, Tactoset Injectable Bone Substitute, and a full portfolio of soft tissue repair products, Anika is well positioned to serve surgeon and patient needs focused on the shoulder and rotator cuff pathology. We look forward to continuing to enhance our comprehensive portfolio of solutions to restore active living, deliver accelerated growth and increase shareholder value.”
Key benefits of RevoMotion include:
- Industry’s smallest diameter threaded glenoid baseplate: The industry’s smallest diameter threaded baseplate3 preserves bone and provides flexibility in positioning, while achieving substantial fixation via a central compression screw.
- Simplified component insertion: RevoMotion’s baseplate and glenosphere designs offer unique insertion methods, allowing the surgeon to slide the components on anteriorly with a positive lock, simplifying the surgical technique and overcoming challenges of other reverse systems.
- Bone preservation and patient personalization: The system includes bone preserving glenoid and humeral designs intended to provide patient personalization via numerous humeral tray offerings which match the native anatomy, similar to other implant system designs in Anika’s Arthrosurface Joint Solutions portfolio, including the flagship OVOMotion with Inlay Glenoid Total Shoulder Arthroplasty System.
- Enhanced efficiency for surgeons and facilities: With its two streamlined instrument trays, RevoMotion appeals to both surgeons and facilities looking to optimize efficiency. The consolidated instrumentation is both Ambulatory Surgical Center (ASC) and hospital friendly, limiting sterile reprocessing and reducing relative costs associated with more complex designs currently in the market.
The RevoMotion RSA System is engineered to uniquely preserve bone, while providing a personalized fit to the patient’s native anatomy. RevoMotion leverages design concepts first introduced by Anika with the Arthrosurface Joint Solutions OVOMotion with Inlay Glenoid. The OVOMotion product line provided new stemless total shoulder arthroplasty concepts to the industry, including a bone conserving, anatomic, non-spherical humeral head with an innovative inlay glenoid design. The RevoMotion system builds on OVO and OVOMotion principles of bone conservation and respecting natural patient anatomy.
“The RevoMotion Reverse Shoulder Arthroplasty System fills a vital place in Anika’s shoulder arthroplasty portfolio, which now offers the full line of solutions to meet my patients’ needs,” said Christopher Baker, M.D., of the Florida Orthopaedic Institute, Tampa, Fla. “RevoMotion offers significant advantages, including a 23mm diameter baseplate, the smallest threaded baseplate on the market. This allows the potential to save glenoid bone-stock and provides flexibility in positioning, allowing me to treat a variety of glenoid morphologies.”
Anika is initially offering the RevoMotion RSA System in the United States through a limited market release, with a full market release expected in late 2023.
Anika Therapeutics is a global joint preservation company focusing on high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, sports medicine soft tissue repair, and bone preserving joint technologies. Anika’s global operations are headquartered outside of Boston.
References
1, 2 2023E and 2022 SmartTRAK Data
3 Data on file